Milenia Biotec

Milenia Biotec is a private, commercial-stage diagnostics company focused on lateral flow assay (LFA) technology. Its core offering is the HybriDetect platform, a universal test strip and development kit that allows researchers and other companies to rapidly prototype and develop custom rapid tests for various targets, including molecular amplicons from techniques like LAMP and RPA. The company generates revenue through direct sales of its development kits and finished diagnostic tests, leverages a global distributor network, and operates in the growing point-of-care and rapid diagnostic testing market. Its strategy combines a platform/tool business with a pipeline of proprietary diagnostic assays.

HybriDetect universal lateral flow assay platform. Pre-configured test strips and kits that enable rapid development of custom tests for proteins, antibodies, and nucleic acid amplicons (e.g., from RPA, LAMP). Simplifies assay development by using universal capture lines and hapten-tagged detection molecules.

Milenia competes in two arenas: as a supplier of LFA development tools against general reagent companies and specialized lateral flow component manufacturers, and as a diagnostics company against established IVD firms in niche areas like HIT testing. Its universal strip approach is a key differentiator in the tools space, but it lacks the commercial scale and breadth of product offerings of larger competitors like Abcam, Thermo Fisher, or Merck.